Bristol-myers Squibb Compnay

Other

Leland Stanford Junior University

Brown University

Bristol Meyers Squibb Company

Syngene International Limited

Bristol-meyers Squibb

Guanglin Luo

John E Macor

Carolyn Diane Dzierba

Ling Chen

Gene Michael Dubowchik

Chaitan Khosla

Rembert Pieper

David E Cane

Amy C Hart

Prasad V Chaturvedula

Jie Chen

Graham S Poindexter

Junqing Guo

Jianliang Shi

William John Pitts

Steven H Spergel

Camilla M Kao

Sing-Yuen Sit

Prasanna Sivaprakasam

George O Tora

Andrew P Degnan

Xiaojun Han

Michael E Mertzman

Yong-Jin Wu

Joanne J Bronson

Scott Hunter Watterson

Brian Lee Venables

Rita Civiello

Jonathan L Ditta

Swanee E Jacutin-Porte

Murugaiah Andappan Murugaiah Subbaiah

Xiang Jun J Jiang

Michael G Yang

Ramesh Kumar Sistla

Susheel Jethanand Nara

Zili Xiao

David Bertil Frennesson

Ramkumar Rajamani

Prasada Rao Jalagam

Soodamani Thangavel

Tarun Kumar Maishal

Jason M Guernon

George N Karageorge

Matthew Reiser Patton

Xirui Hu

Gary W Ashley

Stephen R Bertenshaw

Ronald L Hanson

Richard A Hartz

Katherine S Takaki

Vivekananda M Vrudhula

Brett R Beno

Haiquan Fang

Stephen E Mercer

Zhizhen Barbara Zheng

Hua Gong

David Kenneth Leahy

Vijay T Ahuja

Yu Fan

Thorsten Rosner

Senliang Pan

Carolyn A Weigelt

Lopa V Desai

Shikha Vig

Michael C Mertzman

Charles Mark Conway

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1)

Compounds having formula (I)-(IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Aminotriazolopyridines as kinase inhibitors

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Triazolopyridinyl compounds as kinase inhibitors

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

Biaryl kinase inhibitors

The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications. 

Aminopyrrolotriazines as kinase inhibitors

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, (I) are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein. 

Aminoimidazopyridazines as kinase inhibitors

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3. 

Pyrimidine carboxamides as GSK-3 inhibitors

Compounds having formula (I) (IX), and enantiomers, and diastereomers, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX). 

GSK-3 inhibitors

The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. 

Acyl sulfonamide NaV1.7 inhibitors

The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia. 

Growing community of inventors

Madison, CT, United States of America

Guanglin Luo